Effects of melatonin on carbonic anhydrase from human erythrocytes in vitro and from rat erythrocytes in vivo


BEYDEMİR Ş., GÜLÇİN İ.

Journal of Enzyme Inhibition and Medicinal Chemistry, vol.19, no.2, pp.193-197, 2004 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 2
  • Publication Date: 2004
  • Doi Number: 10.1080/14756360310001656736
  • Journal Name: Journal of Enzyme Inhibition and Medicinal Chemistry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.193-197
  • Keywords: Carbonic anhydrase, Erythrocyte, Human and rat, Melatonin
  • Bilecik Şeyh Edebali University Affiliated: Yes

Abstract

The in vitro effects of melatonin (N-acetyl-5-methoxy-tryptamine) on human carbonic anhydrase isozymes (HCA-I and HCA-II) from human erythrocytes and in vivo effects on rat erythrocytes carbonic anhydrase (CA) were determined. Human erythrocyte carbonic anhydrase isozymes were purified by haemolysate preparation and Sepharose-4B-L tyrosine-sulfanilamide affinity gel chromatography. The HCA-I enzyme, having a specific activity of 7337.5 EU/mg protein, was purified 843-fold with a yield of 60% and the HCA-II enzyme, having a specific activity of 17067 EU/mg protein, was purified 1962-fold with a yield of 22.7%. For in vitro experiments, the enzyme activity was minimal at 2 × 10-4 M melatonin concentration and increased above this concentration. Ten mg kg-1 melatonin was administered intraperitoneally and showed a stimulatory effect on the enzyme. Time-dependent in vivo studies were conducted for melatonin in Sprague-Dawley type rats. It was found that CA activity in the rat erythrocytes was decreased by the melatonin after 1 and 3 hours to 2500 ± 500.0 and 1875 ± 239.4 respectively which were statistically significant (p < 0.05) differences to the control (2660 ± 235.8). However, CA activity was restored to its normal level after 6 h (2666 ± 235.7) (p > 0.05) probably due to metabolism of the melatonin. The findings indicate that melatonin may be pharmacologically useful in some diseases. © 2004 Taylor & Francis Ltd.